David Lewis
Stock Analyst at Morgan Stanley
(2.65)
# 2,127
Out of 4,761 analysts
281
Total ratings
65.47%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $107 → $117 | $134.92 | -13.28% | 23 | Oct 17, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $282.80 | +6.08% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $227.43 | +20.92% | 23 | Oct 11, 2022 | |
| NVRO Nevro | Maintains: Equal-Weight | $55 → $54 | $5.73 | +842.41% | 12 | Aug 4, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $88.78 | +2.50% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $50 → $48 | $0.88 | +5,383.21% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $33.82 | +195.68% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $71.95 | -79.15% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $8.96 | +234.82% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $64.49 | +16.30% | 11 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $45 | $20.87 | +115.62% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $63.02 | -4.79% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $80.28 | +2.14% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $175.64 | +145.39% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $89.94 | +71.23% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $17.84 | +124.22% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $73.30 | +84.17% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $382.78 | -26.85% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $591.79 | -51.84% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $10.01 | +89.81% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $119.44 | -21.30% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $90.31 | -12.52% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $104.83 | +71.71% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $162.30 | +15.22% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $15.45 | +191.26% | 5 | Dec 15, 2020 |
Abbott Laboratories
Oct 17, 2024
Maintains: Equal-Weight
Price Target: $107 → $117
Current: $134.92
Upside: -13.28%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $282.80
Upside: +6.08%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $227.43
Upside: +20.92%
Nevro
Aug 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $54
Current: $5.73
Upside: +842.41%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $88.78
Upside: +2.50%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $50 → $48
Current: $0.88
Upside: +5,383.21%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $33.82
Upside: +195.68%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $71.95
Upside: -79.15%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $8.96
Upside: +234.82%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $64.49
Upside: +16.30%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $20.87
Upside: +115.62%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $63.02
Upside: -4.79%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $80.28
Upside: +2.14%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $175.64
Upside: +145.39%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $89.94
Upside: +71.23%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $17.84
Upside: +124.22%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $73.30
Upside: +84.17%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $382.78
Upside: -26.85%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $591.79
Upside: -51.84%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $10.01
Upside: +89.81%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $119.44
Upside: -21.30%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $90.31
Upside: -12.52%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $104.83
Upside: +71.71%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $162.30
Upside: +15.22%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $15.45
Upside: +191.26%